COST-EFFECTIVENESS OF ENOXAPARIN VERSUS ASPIRIN IN PREVENTING VENOUS THROMBOEMBOLISM
Key Findings from the CRISTAL Trial
The CRISTAL trial compared the costs and benefits of using enoxaparin versus aspirin to prevent symptomatic venous thromboembolism (VTE) after total hip or knee arthroplasty. The study found that:
- Enoxaparin was more effective in preventing symptomatic VTE within 90 days of surgery
- The incremental cost per quality-adjusted life-year (QALY) gained for enoxaparin was AUD$50,567
- There is evidence that enoxaparin may be cost-effective compared to aspirin, especially if the value of avoiding VTE is high and there is a strong likelihood of VTE-related health impairments
Practical Implications and Value
The results of the CRISTAL trial provide practical insights for healthcare decision-makers and clinicians, highlighting the potential benefits of using enoxaparin over aspirin for VTE prevention after hip or knee arthroplasty.
Implementing AI-Driven Solutions
Utilizing AI-driven platforms can help streamline clinical operations, improve patient outcomes, and reduce administrative burdens. DocSym offers a comprehensive knowledge base for clinicians, while our mobile apps support scheduling, treatment monitoring, and telemedicine, enabling clinics to enhance workflows and expand services digitally.
For more information on how AI can revolutionize healthcare practices, visit aidevmd.com.
